ArticleCureus2025
Evaluating the Diagnostic Utility of Cystatin C versus Creatinine in Chronic Kidney Disease: A Cross-Sectional Analysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a progressive condition with high prevalence in India, often driven by diabetes and hypertension. Early detection is critical, yet serum creatinine, the conventional biomarker, is influenced by non-renal factors and lacks sensitivity in early stages. Cystatin C, a low molecular weight protein unaffected by muscle mass or diet, has emerged as a promising alternative. This study evaluates the diagnostic utility of serum cystatin C versus creatinine in detecting and monitoring CKD among Indian patients.
methodsA cross-sectional observational study was conducted at Indira Gandhi Institute of Medical Sciences, Patna, over 18 months, enrolling 150 participants: 75 patients with CKD (grades 3-5) and 75 healthy controls. Serum cystatin C was measured using an enzyme-linked immunosorbent assay and serum creatinine via the kinetic Jaffe method. Estimated glomerular filtration rate (eGFR)
resultsBoth serum cystatin C and creatinine were significantly elevated in patients with CKD compared to controls (p<0.0001). Cystatin C showed a stronger negative correlation with eGFR
conclusionSerum cystatin C is a sensitive and reliable biomarker for CKD detection, demonstrating superior correlation with eGFR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.